Comparison of HY-Ab development between male patients with female (F→M) and male donors (M→M) at 3 months and at 1 year post-HCT
| Hy-Ab development . | F→M at 3 mo (n = 136) . | M→M at 3 mo (n = 60) . | P . | F→M at 1 y (n=92) . | M→M at 1 y (n=50) . | P . |
|---|---|---|---|---|---|---|
| DBY | 26 (19%) | 3 (5%) | .009 | 23 (25%) | 3 (6%) | .006 |
| UTY* | 45 (33%) | 7 (12%) | .002 | 22 (24%) | 1 (2%) | .005 |
| RPS4Y | 25 (18%) | 8 (13%) | .4 | 18 (20%) | 5 (10%) | .16 |
| ZFY | 21 (15%) | 0 (0%) | <.001 | 15 (16%) | 0 (0%) | .001 |
| EIF1AY | 27 (20%) | 0 (0%) | <.0001 | 11 (12%) | 0 (0%) | .008 |
| SMCY* | 50 (37%) | 8 (13%) | .001 | 28 (30%) | 7 (14%) | .04 |
| Multiple HY-Abs (≥2) | 47 (35%) | 6 (10%) | <.001 | 25 (27%) | 3 (6%) | .002 |
| Hy-Ab development . | F→M at 3 mo (n = 136) . | M→M at 3 mo (n = 60) . | P . | F→M at 1 y (n=92) . | M→M at 1 y (n=50) . | P . |
|---|---|---|---|---|---|---|
| DBY | 26 (19%) | 3 (5%) | .009 | 23 (25%) | 3 (6%) | .006 |
| UTY* | 45 (33%) | 7 (12%) | .002 | 22 (24%) | 1 (2%) | .005 |
| RPS4Y | 25 (18%) | 8 (13%) | .4 | 18 (20%) | 5 (10%) | .16 |
| ZFY | 21 (15%) | 0 (0%) | <.001 | 15 (16%) | 0 (0%) | .001 |
| EIF1AY | 27 (20%) | 0 (0%) | <.0001 | 11 (12%) | 0 (0%) | .008 |
| SMCY* | 50 (37%) | 8 (13%) | .001 | 28 (30%) | 7 (14%) | .04 |
| Multiple HY-Abs (≥2) | 47 (35%) | 6 (10%) | <.001 | 25 (27%) | 3 (6%) | .002 |
Values are n (%) unless otherwise noted.
Any seropositivity against 3 UTY and 6 SMCY fragments were scored as positive of UTY and SMCY, respectively.